arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2018-24-2-237-245arthyper-797Research ArticleСтатьиArticlesОценка эффективности периндоприла и индапамида у пациентов с ночной артериальной гипертензией: результаты региональной программы «Хронос»Efficiency of perindopril arginine and indapamide retard in patients with nocturnal hypertension: The results of the study “Chronos”СелезневС. В.SeleznevS. V.

кандидат медицинских наук, ассистент кафедры госпитальной терапии

MD, PhD, Assistant, Department of Internal Diseases

sv.seleznev@gmail.comЯкушинС. С.YakushinS. S.

доктор медицинских наук, профессор, заведующий кафедрой госпитальной терапии

MD, PhD, DSc, Professor, Head, Department of Internal Diseases

Федеральное государственное образовательное учреждение высшего образования «Рязанский государственный медицинский университет» Минздрава России, РязаньРоссияRyazan State Medical UniversityRussian Federation201815052018242237245Copyright © Селезнев С.В., Якушин С.С., 20182018Селезнев С.В., Якушин С.С.Seleznev S.V., Yakushin S.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/797

Цель исследования — oценить антигипертензивную эффективность назначения периндоприла аргинина и индапамида ретард в режиме хронотерапии у пациентов с ночной артериальной гипертензией (АГ). Материалы и методы. В региональную программу «Хронос» открытого, многоцентрового, обсервационного, несравнительного исследования включено 196 пациентов с ночной АГ. В обследование были включены больные АГ 2‑й степени (59,4%) и 3‑й степени (40,6%). При включении в программу вместо текущей антигипертензивной терапии назначался периндоприла аргинин 10мг на ночь и индапамид ретард 1,5 мг утром. Длительность наблюдения составила 3 месяца, контроль эффективности и переносимости терапии проводился через 2 недели, 1 и 3 месяца лечения. Измерение артериального давления (АД) про- водили методом Короткова. Статистическая обработка материала проводилась при помощи программ Microsoft Excel 2012, Statsoft Statistica 10.0. Результаты. В дневные часы медиана систолического АД при включении составила 165,5 (160; 180) мм рт. ст., диастолического АД — 100 (90; 100) мм рт. ст. На фоне лечения периндоприла аргинином и индапамидом ретард уже через 2 недели терапии зарегистрировано статистически значимое (p < 0,05) снижение АД как в дневные, так и в вечерние часы, положительная динамика сохранялась в течение всего времени наблюдения в программе «Хронос». 7 пациентам, которые не достигли целевого АД через 1 месяц приема комбинированной терапии, дополнительно назначались антигипертензивные препараты других классов. Выводы. У всех участников программы выявлено снижение АД как в утреннее, так и в вечернее время. У 73% пациентов отсутствовали утренние подъемы АД. В 60% случаях удалось нормализовать АД у пациентов с резистентной до этого АГ. Переносимость периндоприла аргинина в сочетании с индапамидом ретард хорошая.

Objective. To assess the antihypertensive efficiency of perindopril arginine and indapamide retard in patients with nocturnal hypertension (HTN). Design and methods. In the regional program “Chronos” of the open, multicenter, observational, non-controlled study, we included 196 patients with nocturnal hypertension (2nd degree — 59,4%; 3rd degree — 40,6%). Upon inclusion, instead of the previous therapy the patients received 10 mg perindopril arginine at night and 1,5 mg indapamide retard in the morning. The follow-up was 3 months, the efficiency and tolerability were assessed in 2 weeks, 1 and 3 months of therapy. Blood pressure (BP) was measured by Korotkoff method. Statistical analysis was performed with the use of the programs Microsoft Excel 2012, Statsoft Statistica 10.0. Results. At baseline, daytime median systolic BP was 165,5 (160; 180) mmHg, diastolic BP was 100 (90; 100) mmHg. After 2 weeks of treatment by perindopril arginine and indapamide retard, both daytime and nocturnal BP decreased (p < 0,05). The positive changes maintained for the whole follow-up period. Seven patients did not achieve target BP 1 month later. In these cases, additional therapy (other drug class medications) was prescribed. Conclusion. All patients demonstrated both daytime and nighttime BP decrease. In 73% patients there was no morning BP rise anymore. In 60% BP was normalized in patients who had been considered resistant. The combination therapy was well-tolerated.

артериальная гипертензияантигипертензивная терапияхрономедицинапериндоприлиндапамидhypertensionantihypertensive treatmentchronomedicineperindopril arginineindapamideFinancial support Программа «Хронос» проведена по заказу фармацевтической компании «Сервье» (Франция). / The program “Chronos” is supported by the company Servier (France)ReferencesДиагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010;3:5–26Diagnosis and treatment of hypertension. Russian guidelines (fourth revision). Systemnye Gipertenzii = Systemic Hypertension. 2010;3:5–26. In RussianЧазова И. Е., Жернакова Ю. В., Ощепкова Е. В., Шальнова С. А., Яровая Е. Б., Конради А. О., и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014;10:4–12. doi:https://dx.doi.org/10.18565/cardio.2014.10.4–12Chazova IE, Zhernakova YV, Oschepkova EV, Shalnova SA, Yarovaya E, Konradi AO et al. The prevalence of cardiovascular disease in the Russian population of patients with arterial hypertension. Kardiologiia. 2014;10:4–12. doi:https://dx.doi. org/10.18565/cardio.2014.10.4–12 In RussianLewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age specific relevance of usual blood pressure to vascular mortality: meta-analyses of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9394):1129–1134.Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age specific relevance of usual blood pressure to vascular mortality: meta-analyses of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9394):1129–1134.Petrenko OV. Chronotherapy of hypertension: literature review. Journal of V. N. Karazin` KhNU. 2015;1154:71–78.Petrenko OV. Chronotherapy of hypertension: literature review. Journal of V. N. Karazin` KhNU. 2015;1154:71–78.Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. J Am Med Assoc. 1996;275(19):1507–1513Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. J Am Med Assoc. 1996;275(19):1507–1513Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am J Hypertens. 1998;11 (11 Pt 1):1394–1404.Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am J Hypertens. 1998;11 (11 Pt 1):1394–1404.Sumova A, Sladek M, Polidarova L, Novakova M, Houdek P. Circadian system from conception till adulthood. Progress Brain Res. 2012;199:83–103. doi:10.1016/B978-0-444-59427-3.00005-8Sumova A, Sladek M, Polidarova L, Novakova M, Houdek P. Circadian system from conception till adulthood. Progress Brain Res. 2012;199:83–103. doi:10.1016/B978-0-444-59427-3.00005-8Paulis L, Simko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res. 2007;56(6):671–684.Paulis L, Simko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res. 2007;56(6):671–684.Takeda N, Maemura K. Circadian clock and cardiovascular disease. J Cardiol. 2011;57(3):249–256. doi:10.1016/j.jjcc. 2011.02.006Takeda N, Maemura K. Circadian clock and cardiovascular disease. J Cardiol. 2011;57(3):249–256. doi:10.1016/j.jjcc. 2011.02.006Pickering TG. The clinical significance of diurnal blood pressure variations: Dippers and nondippers. Circulation. 1990;81 (2):700–702.Pickering TG. The clinical significance of diurnal blood pressure variations: Dippers and nondippers. Circulation. 1990;81 (2):700–702.Portaluppi F. The circadian organization of the cardio- vascular system in health and disease. Ind J Exp Biol. 2014;52(05): 395–398.Portaluppi F. The circadian organization of the cardio- vascular system in health and disease. Ind J Exp Biol. 2014;52(05): 395–398.Kario K, Schwartz JE, Gerin W, Robayo N, Maceo E, Pickering TG. Psychological and physical stress-induced cardiovascular resctivity and diurnal blood pressure variation in women with different work shifts. Hypertens Res. 2002;25 (4):543–551.Kario K, Schwartz JE, Gerin W, Robayo N, Maceo E, Pickering TG. Psychological and physical stress-induced cardiovascular resctivity and diurnal blood pressure variation in women with different work shifts. Hypertens Res. 2002;25 (4):543–551.Piper MA, Evans CV, Burda BU Margolis KL, O'Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: an update systematic review for the U. S. Preventive Services Task Force. Ann Int Med. 2015;162 (3):192–204.Piper MA, Evans CV, Burda BU Margolis KL, O'Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: an update systematic review for the U. S. Preventive Services Task Force. Ann Int Med. 2015;162 (3):192–204.Head GA. Ambulatory blood pressure monitoring is ready to replace clinic blood pressure in the diagnosis of hypertension. Pro Side of the Argument. Hypertension. 2014;64(6):1175–1181. doi:10.1161/HYPERTENSIONAHA.114.03882Head GA. Ambulatory blood pressure monitoring is ready to replace clinic blood pressure in the diagnosis of hypertension. Pro Side of the Argument. Hypertension. 2014;64(6):1175–1181. doi:10.1161/HYPERTENSIONAHA.114.03882Fagard RH, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Night–day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J Hum Hypertens. 2009;23(10):645–653. doi:10.1038/jhh.2009.9Fagard RH, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Night–day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J Hum Hypertens. 2009;23(10):645–653. doi:10.1038/jhh.2009.9Roush GC, Fagard RH, Salles GF, Pierdomenico SD, Reboldi G, Verdecchia P et al. Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13 844 patients with hypertension. J Hypertens. 2014;32(12):2332– 2340. doi:10.1097/HJH.0000000000000355Roush GC, Fagard RH, Salles GF, Pierdomenico SD, Reboldi G, Verdecchia P et al. Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13 844 patients with hypertension. J Hypertens. 2014;32(12):2332– 2340. doi:10.1097/HJH.0000000000000355Kario K., Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107(10):1401–1406.Kario K., Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107(10):1401–1406.Redon J. The importance of 24-hour ambulatory blood pressure monitoring in patients at risk of cardiovascular events. High Blood Press Cardiovasc Prevent. 2013;20(1):13–18. doi:10.1007/ s40292-013-0006-3Redon J. The importance of 24-hour ambulatory blood pressure monitoring in patients at risk of cardiovascular events. High Blood Press Cardiovasc Prevent. 2013;20(1):13–18. doi:10.1007/ s40292-013-0006-3Xie JC, Yan H, Zhao Y-X, Liu XY. Prognostic value of morning BP surge in clinical events: a meta-analysis of longitudinal studies. J Stroke Cerebrovasc Dis. 2015;24(2):362–369. doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.09.001Xie JC, Yan H, Zhao Y-X, Liu XY. Prognostic value of morning BP surge in clinical events: a meta-analysis of longitudinal studies. J Stroke Cerebrovasc Dis. 2015;24(2):362–369. doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.09.001Vernon G. The chronotherapy of hypertension: or the benefit of taking blood pressure tablets at bedtime. Br J Gen Pract 2017;67 (657):171. doi:https://doi.org/10.3399/bjgp17X690269Vernon G. The chronotherapy of hypertension: or the benefit of taking blood pressure tablets at bedtime. Br J Gen Pract 2017;67 (657):171. doi:https://doi.org/10.3399/bjgp17X690269Roush GC. Fapohunda J, Kostis JB. Evening dosing of antihypertensive therapy to reduce cardiovascular events — a third type of evidence based on a systematic review and meta-analysis of randomized trials. J Clin Hypertens. 2014;16(8):561–568. doi:10. 1111/jch.12354Roush GC. Fapohunda J, Kostis JB. Evening dosing of antihypertensive therapy to reduce cardiovascular events — a third type of evidence based on a systematic review and meta-analysis of randomized trials. J Clin Hypertens. 2014;16(8):561–568. doi:10. 1111/jch.12354Smolensky MH, Hermida RC, Ayalab DE, Tiseo R, Portaluppi F. Administration–time-dependent effects of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press Monit. 2010;15(4):173–180. doi:10.1097/ MBP.0b013e32833c7308Smolensky MH, Hermida RC, Ayalab DE, Tiseo R, Portaluppi F. Administration–time-dependent effects of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press Monit. 2010;15(4):173–180. doi:10.1097/ MBP.0b013e32833c7308Лукьянов М. М., Бойцов С. А., Якушин С. С., Марцевич С. Ю., Воробьев А. Н., Загребельный А. В. и др. Сочетанные сердечно-сосудистые заболевания и антигипертензивное лечение у больных с артериальной гипертонией в амбулаторно-поликлинической практике (по данным регистра РЕКВАЗА). Рациональная фармакотерапия в кардиологии. 2016; 12(1):4–15.Lukyanov MM, Boitsov SA, Yakushin SS, Martsevich SY, Vorobiev AN, Zagrebelny AV et al. Concomitant cardiovascular diseases and antihypertensive treatment in outpatient practice (by the RECVASA Registry data). Rational Pharmacotherapy in Cardiology. 2016;12(1):4–15. In RussianFox KM; European trial ON reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–788.Fox KM; European trial ON reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–788.Rodriguez-Granillo GA, De Winter S, Bruining N, Ligthart JM, García-García HM, Valgimigli M et al. Effect of perindopril on coronary remodeling: insights from a multicentre, randomized study. Eur Heart J. 2007;28(19):2326–2331.Rodriguez-Granillo GA, De Winter S, Bruining N, Ligthart JM, García-García HM, Valgimigli M et al. Effect of perindopril on coronary remodeling: insights from a multicentre, randomized study. Eur Heart J. 2007;28(19):2326–2331.Morgan T, Anderson A, Jones E. The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night. J Hypertens. 1997;15(2):205–211.Morgan T, Anderson A, Jones E. The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night. J Hypertens. 1997;15(2):205–211.Леонова М. В., Белоусов Д. Ю., Штейнберг Л. Л. и аналитическая группа исследования ПИФАГОР. Анализ врачебной практики проведения антигипертензивной терапии в России (по данным исследования ПИФАГОР III). Фарматека 2009;12:98–103.Leonova MV, Belousov DYu, Steinberg LL, and the analytical group of the PIFAGOR study. Analysis of the clinical routine practice of antihypertensive therapy in Russia (according to the PIFAGOR III study). Pharmateka 2009;12:98– 103. In RussianМартынюк Т. В., Колос И. П., Чазова И. Е. от имени соисследователей программы СТРАТЕГИЯ. Эффективность и безопасность фиксированной комбинации малых доз периндоприл/индапамида у пациентов с артериальной гипертонией в условиях реальной клинической практики (многоцентровое, открытое, проспективное исследование СТРАТЕГИЯ). Кардиоваскулярная терапия и профилактика. 2007;8:21–27Martyniuk TV, Kolos IP, Chazova IE. on behalf of the co-investigators of the STRATEGY program. Efficacy and safety of a fixed combination of low-dose of perindopril/indapamide in patients with arterial hypertension in real clinical practice (multicentre, open, prospective study STRATEGY). Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2007;8:21–27. In RussianЧазова И. Е., Ратова Л. Г., Мартынюк Т. В. Первые итоги Российского исследования СТРАТЕГИЯ А (Российская программа по оценке эффективности нолипрела А форте у пациентов с артериальной гипертонией высокого риска и недостаточным контролем артериального давления) — на пути оптимизации антигипертензивной терапии у больных АГ высокого риска. Системные гипертензии 2010;4:41–48Chazova IE, Ratova LG, Martynyuk ТV. The first results of the Russian study STRATEGY A (Russian program for assessing the efficacy of Noliprel A Forte in patients with high-risk arterial hypertension and insufficient control of blood pressure) is on the way to optimize antihypertensive therapy in high-risk hypertension patients. Systemnye Gipertenzii = Systemic hypertension. 2010;4:41–48. In RussianMourad JJ, Lameira D, Guillausseau PJ. Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. Vasc Health Risk Manag. 2008;4 (2):4443–4451.Mourad JJ, Lameira D, Guillausseau PJ. Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. Vasc Health Risk Manag. 2008;4 (2):4443–4451.Dahlöf B, Gosse P, Gueret P, Dubourg O, de Simone G, Schmieder R et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23(11):2063–2070.Dahlöf B, Gosse P, Gueret P, Dubourg O, de Simone G, Schmieder R et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23(11):2063–2070.Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G et al. Preterax in albuminuria regression (PREMIER) study Group. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003;41(5):1063–1071.Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G et al. Preterax in albuminuria regression (PREMIER) study Group. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003;41(5):1063–1071.Patel A; ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370(9590):829–840.Patel A; ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370(9590):829–840.

The authors declare that there are no conflicts of interest present.